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Received May 11, 2012; accepted August 3, 2012AbstractBackground: Although the mammalian central nervous system contains numerous matrix metalloproteinases (MMPs), the significance of each
MMP relative to nociception remains obscure. Working from the hypothesis that MMPs may be involved in activity-dependent reorganization
during neuronal modulation, we explored the role of each MMP following neuropathological injury by establishing MMP expression profiles in
a murine model for neuropathic pain.
Methods: Sciatic nerves of adult male C57BL/6C mice were partially ligated, and their responses to mechanical and radiant heat stimulations
were observed at 1, 3, 7, and 14 days. The expression of several nociception-related MMPs (MMP-2, MMP-9, MMP-12, MMP-17, and MMP-
24) in the spinal cord was detected by immunohistochemical analysis, Western blotting, and real-time polymerase chain reaction. In addition, the
potential of GM6001, a general inhibitor of MMP peritoneal administration, to modulate nociceptive pain responses in a chronic neuropathic
pain model in mice was also investigated.
Results: MMP-2, 9, 17, and 24, but not MMP-12, were expressed in the murine spinal cord. MMP-9 was constitutively expressed in neurons and
microglial cells, immediately upregulated after nerve injury, and returned to baseline levels at day 3. Expression of MMP-2, MMP-17, and
MMP-24 gradually increased after nerve injury. Morphologically, MMP-2-positive cells were glial-like cells. MMP-17 and MMP-24 expression
was widespread in gray matter, neurons, and microglial cells, and concentrated in the marginal zone of the dorsal horn and in small capillaries.
Peritoneal administration of GM6001 resulted in significantly attenuated thermal hyperalgesia and tactile allodynia induced by nerve injury.
Conclusion: Expression of several nociception-related MMPs was differentially regulated both temporally and spatially following nerve injury.
These results suggest that neuronal remodeling requires concerted expression of particular MMPs in specific temporal and spatial patterns, which
may be necessary for neuronal plasticity and/or recovery.
Copyright  2013 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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logical functions.1e3 The influence of MMPs is widespread,
affecting adhesion molecules, cytokines, receptors, and also
having an impact on the pain system and the release of pain-
related substances, including tumor necrosis factor-a (TNF-a)
and substance P.2,4,5 Several lines of evidence suggest that the
mammalian central nervous system (CNS) contains numerous
MMPs, and that their expression can be upregulated after anhinese Medical Association. All rights reserved.
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injury.6e8 Moreover, the upregulated expression of MMPs
during nerve injuries often leads to several undesirable out-
comes.9,10 However, the importance of their sequential
expression and their biological role during nociceptive signal
transmission following injury remain obscure.
The participation of MMPs during nerve injury is supported
by other reports in which MMPs were differentially distributed
and expressed in both mouse and rat neuropathic pain
models.9,11,12 Therefore, one reasonable hypothesis that
emerges from these findings is that MMPs may actively par-
ticipate in different pathological states and may be involved in
activity-dependent reorganization during neuronal modulation.
To explore the role of different MMPs following neuro-
pathological injury, the expression profiles of MMPs in a mu-
rine model of neuropathic pain would need to be established.
This report documents the temporal and spatial expression of
MMPs in the spinal cord following peripheral partial sciatic
nerve ligation (PSNL) in mice.
2. Methods2.1. Animals and preparationAdult male C57BL/6C mice, 8e10 weeks old and weighing
15e20 g, were purchased from Charles River in Taiwan. All
procedures were reviewed and approved by the Institutional
Animal Care and Use Committee at Chang Gung Memorial
Hospital, and animals were treated in accordance with the
Ethical Guidelines for Investigations of Experimental Pain in
Conscious Animals, as issued by the International Association
for the Study of Pain. Animals were randomly assigned to one
of two groups that were subjected to right-side PSNL or sham
control. Thermal hyperalgesia and tactile allodynia were
observed for 1, 3, 7, and 14 days after surgery. In parallel with
behavioral experiments, the expression profiles of MMPs in
the spinal cord were estimated by immunohistochemical
analysis, Western blotting, and real-time polymerase chain
reaction (PCR). During experiments, animals were housed in
individual ventilation cages in a qualified satellite facility.
Postoperative wound care was examined daily, and animals
with signs of wound infection or dehiscence were excluded
from the study. At the end of the protocol, all animals were
killed by an overdose of pentobarbital (by peritoneal injection)
with subsequent cervical dislocation.2.2. Surgical proceduresThe animal model for chronic neuropathic pain was pre-
pared as previously described for rats and mice.13,14 All ani-
mals were anesthetized with 1.5e2% isoflurane, the right
sciatic nerve was exposed at the upper thigh level, and half of
the diameter of the nerve was tightly ligated using a 6e0
polydioxanone suture. Sham surgeries were also performed by
exposing the sciatic nerve without ligation. After ligation,
muscle and skin layers were closed and animals were allowed
to recover in their cages.2.3. Nociceptive testsThe measurement of pain behaviors has been previously
described, and minor modifications were made to that protocol
in the present study.15,16 In brief, animals (n ¼ 12/group) were
placed individually on an elevated plastic mesh floor covered
with a clear plastic cage and allowed to acclimate to the
environment for at least 60 minutes. Withdrawal responses to
punctuate mechanical stimulation were determined using
calibrated Semmes-Weinstein Von Frey filaments (Stoelting,
Wood Dale, IL, USA). Stimulation was applied to the distal
portion of the plantar aspect of the hindpaw. Each stimulus
was applied from 0 g to the point at which a withdrawal
response was observed or until the cutoff value of 20 g was
reached. These tests were repeated three times for each mouse,
with a 5-minute resting period. The mean value of these tests
was considered as the withdrawal threshold. Withdrawal la-
tencies to heat stimulation were assessed by applying
a focused radiant heat source (Model-336 IITC Paw and Tail
Flick Analgesia Meter; IITC Inc., Woodland Hills, CA, USA).
The heat stimulus was applied to the distal portion of the
plantar aspect of the hindpaw. The cutoff value was set at 15
seconds. Each mouse was tested three times, with 5e10-
minute resting periods between each test, to obtain the aver-
age paw withdrawal latency.2.4. Treatment with an MMP inhibitorDifferent groups of mice (n ¼ 12/group) were treated with
either GM6001, a general inhibitor of MMPs [Chemicon,
Temecula, CA, USA; 100 mg/kg in 4% methylcellulose,
intraperitoneally (i.p.)], or vehicle (4% methylcellulose, i.p.) 2
hours before PSNL or sham surgery, followed by additional
treatment every 24 hours for an additional 3 days. The pro-
tocol of GM6001 treatment was determined according to
a previous experimental report, with minor modifications.
Subsequently, nociceptive behavior was observed for 1, 3, 7,
and 14 days after the surgery.2.5. Immunohistochemical analysisAnimals were anesthetized and killed at 1, 3, 7, and 14 days
after nerve ligation and spinal cords were ejected from the
vertebral column using a cold-saline-filled syringe. The L4eL5
spinal cord segments were fixed in 4% paraformaldehyde for 6
hours. After subsequent dehydration, samples were embedded
in paraffin, sliced into 5-mm sections with an automatic micro-
tome, immersed in xylene, and rehydrated. Rehydrated tissue
sections were incubated in sodium citrate buffer (10mMsodium
citrate, 0.05% Tween-20, pH 6.0) for 30 minutes at 95e100C
for antigen retrieval, followed by treatment with 0.3% hydrogen
peroxide and blocking with 10% normal goat serum (NGS;
Vector Laboratories, Burlingame, CA, USA). Tissue section
samples were then incubated with rabbit polyclonal anti-MMP-
2 (1:1000; Torrey Pines Biolabs, San Diego, CA, USA), anti-
MMP-9 (1:2000; ANAWA, Zurich, Switzerland), anti-MMP-
12, anti-MMP-17, or anti-MMP-24 (1:500, BioVision,
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buffered saline (PBS) containing 0.3% Triton-X 100 and 3%
NGS at 4C for 24e36 hours. After washing, the sections were
incubated in biotinylated goat anti-rabbit immunoglobulin G
(IgG) secondary antibody (Vector Laboratories, Burlingame,
CA, USA) at 1:200 using an Elite VECTASTAIN ABC kit
(Vector Laboratories, Burlingame, CA, USA). Sections were
developed with 0.05% diaminobenzidine in PBS for 3e10
minutes. Images were captured using a digital camera (Nikon
DXM 1200 with Eclipse E800; Nikon Instruments Inc., Mel-
ville, NY, USA).
To examine coexpression of MMPs in various cells in the
spinal cord, sections were respectively incubated with differ-
ent MMP antibodies and with goat anti-Iba1 (1:400; Abcam,
Cambridge, MA, USA), mouse antineuronal-specific nuclear
protein (NeuN) (1:1000; Millipore Bioscience Research Re-
agents, Temecula, CA, USA), or mouse anti-glial fibrillary
acidic protein (anti-GFAP; 1:5000, Millipore Bioscience
Research Reagents) antibody overnight at 4C under gentle
agitation. Sections were then incubated with the respective
secondary antibodies: donkey antigoat (1:100), goat antirabbit
conjugated with Rhodamine Red-X (1:200); goat antimouse,
donkey antirabbit, and goat antirat conjugated with fluorescein
isothiocyanate (1:200; all from Jackson ImmunoResearch
Laboratories, Inc., West Grove, PA, USA). Nonspecific
staining was determined by excluding primary antibodies.
Thereafter, sections were washed and cover slips were
mounted on the glass slides with ProLong antifade medium
(Molecular Probes, Inc., Eugene, OR, USA). Images were
captured using a fluorescence microscope operated by Case
Data Manager Expo 4.5 software (Leica DM2500; Leica
Microsystems Inc., Houston, TX, USA).2.6. Western blot analysisThe ipsilateral halves of spinal dorsal horns were weighed,
homogenized in buffer A [20 mM 4-(2-hydroxyethyl)-1-
piperazine ethanesulfonic acid (HEPES), pH 7.5, 150 mM
NaCl, 3 mM MgCl2, 1 mM b-mercaptoethanol, 5 mg/mL leu-
peptin, 5 mg/mL pepstatin A, 1 mg/mL aprotinin, and 0.1 mM
phenylmethylsulfonyl fluoride], and centrifuged (15,000 g,
4C) for 10minutes. The supernatants were collected and stored
at 80C for later analysis. The pellets were resuspended and
agitated in buffer B (25mMHEPES, pH 7.4, 150mMNaCl, and
1% Triton X-100) at 4C for 4 hours and then centrifuged
(15,000 g, 4C) for 10 minutes. The supernatants were collectedTable 1
Sequences of the gene-specific primers used for analysis by quantitative real-time
Gene GenBank accession numbers Primer fo
b-Actin (NM_007393) ACCCTA
MMP-2 (NM_008610.2) GTCTTT
MMP-9 (NM_013599.2) AGTCCG
MMP-12 (NM_008605.3) TGTGGA
MMP-17 (NM_011846.4) CCCAAC
MMP-24 (NM_010808.3) CTGTGG
MMP ¼ matrix metalloproteinases; PCR ¼ polymerase chain reaction.and stored at 80C for further analysis. Each sample was first
separated by sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis (30 mg of total protein per lane) and then transferred
onto nitrocellulose membranes (Hybond polyvinylidene
difluoride membranes; Amersham Pharmacia Biotech, San
Francisco, CA, USA). After blockingwith 5% low-fatmilk for 1
hour at room temperature (22e24 C), membranes were incu-
bated with an individual primary antibody (1:1000 for anti-
MMP-2, 1:2000 for anti-MMP-9, and 1:500 for anti-MMP-12,
17, and 24) and anti-b-actin antibody (1:10,000, Santa Cruz
Biotechnology, Inc., San Francisco, CA, USA) for another hour
and then subjected to three washes. Membranes were further
incubated with horseradish peroxidase-conjugated goat anti-
rabbit IgG secondary antibodies (Jackson ImmunoResearch
Laboratories, Inc.) at room temperature for 1 hour, followed by
three washes. Finally, the immune complexes were detected
using anECLplus chemiluminescent kit (AmershamPharmacia
Biotech). The intensity of the immunoreactive bands was
quantified using ImageQuant software (Molecular Dynamics,
Sunnyvale, CA, USA) and normalized to b-actin in each
sample.2.7. Total RNA isolation and quantitative real-time PCRDifferent groups of animals (n ¼ 6/group) were killed at 0,
1, 3, 7, and 14 days after PSNL for quantitative real-time PCR
analysis as described in previous reports.16,17 Spinal cords
were harvested and homogenized in 0.8e1 mL TRIzol (Invi-
trogen, Carlsbad, CA, USA). Total RNAs were extracted using
the PureLink Micro-to-Midi Total RNA Purification System
(Invitrogen). Spectrophotometric analysis was used to deter-
mine the total RNA concentrations of each sample, and all
RNA samples were pretreated with DNase I (Invitrogen)
before complementary DNA (cDNA) synthesis. First-strand
cDNAs of each sample were reverse transcribed using the
SuperScript III first-strand synthesis SuperMix system (Invi-
trogen). Specific primer for MMPs (MMP-2, MMP-9, MMP-
12, MMP-17, and MMP-24) were designed for quantitative
PCR using Oligo 6.67 (Molecular Biology Insights Inc., West
Cascade, CO, USA) (Table 1). The primers for the b-actin
gene were also designed and used as an endogenous control
for normalization. Each reaction was performed with 10 mL of
Master Mix (DyNAmo, Flash Probe qPCR Kit; Finnzymes,
Espoo, Finland), 1 mL of a mix containing two primers (10 mM
each), and a template (0.2 mM) for each specific cDNA sam-
ple. The quantitative PCRs were conducted using the ChromoPCR.
rward (50 to 30) Primer reverse (50 to 30)
AGGCCAACCGTGAA ATGGCGTGAGGGAGAGCATAG
GATGGCATCGCTCAG GGCCTCATACACAGCGTCAAT
GCAGACAATCCT CTCCTTATCCACGCGAATGAC
GTGCCCGATGTA CATCAGCAGAGAGGCGAAATG
AATCGGTCTAGCACT GGGTACCCTTCCTCTACGTT
GCAAAACCTACT ACGCTCAGTTTCTGGTTGTCA
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Hercules, CA, USA). Linearity and efficiency of PCR ampli-
fication were assessed using standard curves generated by
increasing amounts of cDNA. Melt-curve analyses were also
conducted to estimate consistency of product formation and
amplification of nonspecific products. The threshold for
detection of PCR products was set in the log-linear phase of
amplification, and the threshold cycle (CT) was determined for
each reaction. The levels of the target messenger RNAs
(mRNAs) were quantified relative to the level of the house-
keeping gene (b-actin) using the comparative CT (DCT)
method for each sample. Finally, the relative mRNA expres-
sion was presented as a ratio of the baseline expression level (0
days).2.8. Statistical analysisFig. 1. Behavioral changes in mice at 14 days following PSNL. Measurement
of behavioral hypersensitivity in GM6001, a general inhibitor of MMPsAll data were expressed as mean  standard deviation.
Changes recorded from behavioral experiments as well as
changes in protein-band intensity and in real-time qPCR
results were tested with two-way analysis of variance with
time points as a within-subjects factor, followed by Dunnett
tests for multiple comparisons at individual time points. The
results of flow cytometry were analyzed using ManneWhitney
U tests to test specific hypotheses about differences between
each test group and its corresponding control group. Statistical
analysis was conducted using GraphPad Prism 5.0 software
(GraphPad, San Diego, CA, USA). Statistical results were
considered significant if p < 0.05.
3. Results(100 mg/kg in 4% methylcellulose, i.p.), or vehicle (4% methylcellulose, i.p.)-
treated mice 14 days following PSNL or sham surgery. Baseline values of both
(A) mechanical and (B) thermal hypersensitivities were not different within
3.1. Mice subjected to PSNL demonstrated reduced
withdrawal latency in response to nociceptive stimuligroups. The thermal hyperalgesia latencies and tactile allodynia thresholds in
the ipsilateral hindpaw of PSNL animals were significantly decreased at all
postlesion time points when compared with those of the baseline value
(***p < 0.05), compared with sham control group (*p < 0.05), and compared
with GM6001-treated mice (**p < 0.05). Data are presented as mean, n ¼ 12
in each data set. i.p. ¼ intraperitoneal; MMPs ¼ matrix metalloproteinases;
PSNL ¼ partial sciatic nerve ligation.The response time at the nerve lesion site (ipsilateral
hindpaws) to nociceptive stimuli was assessed and compared
with those collected from sham-operated animals. Fig. 1
shows that the mean thresholds did not differ between
groups before PSNL. Mice subjected to PSNL demonstrated
a significant reduction in withdrawal latency to both thermal
and mechanical stimuli from 1 to 14 days after PSNL.3.2. PSNL elicited increasing expressions of MMPs in
the corresponding segmentsImmunoreactivities of MMP-2, -9, -17, and -24 were
detected in the spinal cords of mice receiving PSNL (Fig. 2).
Expression of MMP-2, 17, and -24 gradually increased after
nerve injury. Conversely, MMP-9 was constitutively expressed
and immediately upregulated after nerve injury, returning to
baseline levels at day 3. MMP-12 expression was not detected
in spinal cord samples at any time point. The observed MMP
expression patterns were further supported at the mRNA and
protein levels by real-time PCR (Figs. 3e6B) and Western
blotting (Fig. 7). These results indicated lower levels of MMP-2, -9, -17, and -24 in the sham control as compared with the
PSNL groups.3.3. Peritoneal administration of GM6001, a general
inhibitor of MMPs, resulted in significantly attenuated
thermal hyperalgesia and tactile allodynia induced by
nerve injuryTo establish whether peritoneal administration of an MMP
inhibitor could modulate nociceptive pain responses, with-
drawal latencies and thresholds to heat and punctuate me-
chanical stimulation were measured in animals treated with
GM6001, a general inhibitor of MMPs, or vehicle in PSNL, or
sham control animals. Results indicated that before treatment,
mean withdrawal latencies did not differ between GM6001-
Fig. 2. Immunoreactivities of MMP-2, MMP-9, MMP-12, MMP-17, and MMP-24 in the spinal cord dorsal horn after partial sciatic nerve ligation (PSNL). The
expression levels of MMP-2, MMP-9, MMP-17, and MMP-24 were significantly increased in the dorsal horn following PSNL. Expression of MMP-9 was
increased over the first 3 days after nerve ligation and then gradually decreased (B1eB5). MMP-2, MMP-17, and MMP-24 were mainly expressed at later periods
(A1eA5, D1eD5, and E1eE5). Expression of MMP-12 was not detected at any point during the observation period (C1eC5). I ¼ ipsilateral, C ¼ contralateral;
MMP ¼ matrix metalloproteinase; scale bar ¼ 250 mm.
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days, withdrawal latencies and thresholds were substantially
increased in the paws of GM6001-treated animals but not in
vehicle-injected animals. When compared with vehicle-treated
animals, GM6001-treated animals demonstrated a statistically
significant ( p < 0.05) increase in withdrawal latencies and
thresholds, which were maintained for the duration of the
experiment (Fig. 1). However, treatment with GM6001 did not
alter the threshold to stimulus-evoked response in sham sur-
gery animals. These data suggest that animals treated with
GM6001 demonstrated significantly attenuated thermal
hyperalgesia and tactile allodynia induced by PSNL.3.4. Temporally regulated differential expression ofMMPsFurther analysis based on immunohistochemical results
revealed that there were substantial differences in the
expression patterns between each of the MMPs (Fig. 2).
MMP-9 was constitutively expressed before PSNL, immedi-
ately upregulated after nerve injury (Fig. 2-B2), and returned
to baseline during days 7e14 (Fig. 2-B4 and B5). These ob-
servations were further supported by the mRNA and protein
assays, where noticeable expression of MMP-9 was detected
during days 1e3 (Figs. 4B and 7). Conversely, the expression
patterns of MMP-2, -17, and -24 gradually increased after
nerve injury, and their peak expression was mainly detected inlater phases. This pattern of expression was also confirmed by
the results of our Western blotting and real-time PCR analysis,
where the expression of MMP-2, -17, and -24 in the spinal
cord was progressively upregulated after nerve ligation
throughout the entire time course studied (Figs. 3B,5B,6B, and
7). In contrast to the other MMPs, the expression of MMP-12
at the mRNA and tissue levels was not detected over the entire
time course in either the control or sciatic nerve ligation
groups (Fig. 2-C1eC5).3.5. Spatially regulated differential expression of MMPsSubstantial differences in the cellular expression patterns
between each of the MMPs were also detected (Fig. 2). The
expressions of MMP-2 and MMP-9 were widespread in the
gray matter, and the distribution pattern was even. They were
mainly expressed in cell bodies, as opposed to interstitial areas
within the gray matter. Moreover, cells with positive immu-
noreactivities to the MMP-2 antibody were morphologically
glial like (Fig. 3A), and the MMP-9 antibody positive cells
were mostly neuron like (Fig. 4A) and predominantly located
in laminae I and II of the dorsal horn. The expression patterns
of MMP-17 and MMP-24 were also widespread in the gray
matter but predominantly localized to the marginal zone of
dorsal lamina (Figs. 5 and 6A). In addition to their expression
in neuron-like cells, MMP-17 and MMP-24 were also
Fig. 3. (A) Histopathological features and (B) time course of changes in
expression of spinal cord MMP-2 mRNAs in animals following PSNL or sham
surgery. MMP-2 was predominantly expressed in glial-like cells (white arrow),
with a lesser amount of expression observed in the neurons (black arrow).
Total RNA and cDNA were prepared at different time points, and the
expression profile of MMP-2 in animals following PSNL or sham surgery was
determined by real-time PCR. The b-actin gene was used as an endogenous
control for normalization of the amount of total RNA in each sample
(mean  SD, n ¼ 6 in each group). *p < 0.05 relative to sham control,
**p < 0.05 compared with baseline value. cDNA ¼ complementary DNA;
mRNAs ¼ messenger RNAs; MMPs ¼ matrix metalloproteinases;
PCR ¼ polymerase chain reaction; PSNL ¼ partial sciatic nerve ligation.
Fig. 4. (A) Histopathological features and (B) time course of changes in
expression of spinal cord MMP-9 mRNAs in animals following PSNL or sham
surgery. MMP-9 expression was primarily detected in the neuron-like cells of
the dorsal horn, especially in laminae 1 and 2, which are abundant in sensory
neurons (black arrows). Total RNA and cDNAwere prepared at different time
points, and the expression profile of MMP-9 in animals following PSNL or
sham surgery was determined by real-time PCR. The b-actin gene was used as
an endogenous control for normalization of the amount of total RNA in each
sample (mean  SD, n ¼ 6 in each group). *p < 0.05 relative to sham control,
**p < 0.05 compared with baseline value. cDNA ¼ complementary DNA;
mRNAs ¼ messenger RNAs; MMPs ¼ matrix metalloproteinases;
PCR ¼ polymerase chain reaction; PSNL ¼ partial sciatic nerve ligation.
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the dorsal horn (Figs. 5 and 6A). These differences in cellular
expression patterns were further supported by double immu-
nostaining demonstrating MMP-2 expression in GFAP-
positive astrocytes (Fig. 8I) but not in neurons or microglial
cells (Fig. 8A and E). MMP-9, MMP-17, and MMP-24 were
expressed in neurons (Fig. 8B, C, and D) as well as in
microglial cells (Fig. 8F, G, and H) but not in astrocytes
(Fig. 8J, K, and L).
4. Discussion
In this study, the differential expression profiles of several
pain-related MMPs (MMP-2, -9, -12, -17, and -24) were
established in mice following PSNL. In addition, each of these
MMPs demonstrated distinct temporal and spatial reactions
following sciatic nerve injury. As these MMPs have been
implicated in pathological pain development,9,11,12,18e20 the
alteration of their expression upon PSNL reflected their roles
in the neuropathological process involving both neurons and
glial cells.10,21e25 The distinctive expression pattern of each
MMP indicated a dedicated MMP machinery, which wasdifferentially controlled and organized to modify and remodel
the pathological process of neuropathic injury.
Our results showed that MMP-2 was constitutively
expressed at a low level in sham animals and that its expres-
sion was increased over the first 2 weeks following injury.
These findings are in contrast to recent data collected from
both rat peripheral nerve and spinal cord injury models, in
which upregulation of MMP-2 was observed at later stages of
injury.9,19,26 Comparing the spatial and temporal expression
patterns, the results of the present study showed a distribution
and pattern of MMP-2 expression similar to those in previous
reports, with the exception that the expression level was
consistently and gradually increased after injury. Although
MMP-2 is a well-known member of the gelatinase family and
is responsible for degradation of several pain-related media-
tors such as TNF-a, interleukin-1b (IL-1b), and substance P,2
its role in neuropathic pain remains controversial. For exam-
ple, local application or i.p. injection of an MMP inhibitor
may reduce the level of neuropathic pain.27,28 Conversely,
intrathecal administration of exogenous MMP-2 to the spinal
cord produced analgesic effects in a rat model of acute pain.18
A recent study demonstrated that intrathecal administration of
Fig. 5. (A) Histopathological features and (B) time course of changes in
expression of spinal cord MMP-17 mRNAs in animals following PSNL or
sham surgery. MMP-17 was detected in the neuron-like cells (black arrow),
and in the small capillary vasculature and matrix of the dorsal horn (white
arrow). Total RNA and cDNA were prepared at different time points, and the
expression profile of MMP-17 in animals following PSNL or sham surgery
was determined by real-time PCR. The b-actin gene was used as an endoge-
nous control for normalization of the amount of total RNA in each sample
(mean  SD, n ¼ 6 in each group). *p < 0.05 relative to sham control,
**p < 0.05 compared with baseline value. cDNA ¼ complementary DNA;
mRNAs ¼ messenger RNAs; MMPs ¼ matrix metalloproteinases;
PCR ¼ polymerase chain reaction; PSNL ¼ partial sciatic nerve ligation.
Fig. 6. (A) Histopathological features and (B) time course of changes in
expression of spinal cord MMP-24 mRNAs in animals following PSNL or
sham surgery. MMP-24 was also detected in the neuron-like cells (black
arrow), and in the small capillary vasculature and matrix of the dorsal horn
(white arrow). Total RNA and cDNA were prepared at different time points,
and the expression profile of MMP-24 in animals following PSNL or sham
surgery was determined by real-time PCR. The b-actin gene was used as an
endogenous control for normalization of the amount of total RNA in each
sample (mean  SD, n ¼ 6 in each group). *p < 0.05 relative to sham control,
**p < 0.05 compared with baseline value. cDNA ¼ complementary DNA;
mRNAs ¼ messenger RNAs; MMPs ¼ matrix metalloproteinases;
PCR ¼ polymerase chain reaction; PSNL ¼ partial sciatic nerve ligation.
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cleavage and astrocyte activation.29 These results are con-
sistent with findings from the present study, which demon-
strated MMP-2 expression predominantly in astrocytes relative
to neurons. Therefore, MMP-2 may play an important role in
the inflammatory and neuropathic pain processes.
In the present study, continual low-level expression and
subsequent upregulation of MMP-9 was observed over the first
3 days after PSNL. This increased expression of MMP-9 in the
injured peripheral nerve and spinal cord has been demon-
strated in rat peripheral nerve and spinal cord injury
models.9,10,19,29 Expression in the early stage of injury sup-
ports the hypothesis that MMP-9 participates in the inflam-
matory response to neuropathic pain via IL-1b cleavage and
microglial activation.29 However, results from the present
study revealed that the upregulation of MMP-9 was detected
mainly in neurons of the dorsal horn. Specifically, this upre-
gulation was detected predominantly in laminae I and II, in
which the cellular components mainly comprised sensory
neurons. Known as gelatinase-B, MMP-9 cleaves numerous
substrates (TNF-a, IL-1b, interferon-g, and substance P) to
generate active mediators and participates in the inflammationprocess by cleavage of these proteins.2,30 Plausibly, an MMP-9
deficiency could affect axonal outgrowth, migration, and
apoptosis in the developing brain and promote neural regen-
eration.2,22,31,32 Results from several reports have demon-
strated that suppression of MMP-9 under pathological
conditions via different interventions resulted in attenuation of
the severity of disease and preservation of organ func-
tion.10,12,27,28,33 Conversely, MMP-9 has also been postulated
to play a protective role during pathological conditions.34,35
Thus, the controversial role of MMP-9 remains unsolved.
The results of the present study were in line with data col-
lected from MMP-9 knockout (KO) mice, in which the MMP-
9 deletion protected peripheral nerve fibers by preservation of
myelin basic protein levels and reduced spontaneous pain
behaviors in a murine model of peripheral nerve damage.36
Additional research will be required in order to more fully
elucidate the role(s) of MMP-9 in the CNS.
In contrast to previous studies using a spinal cord injury
model, in which the MMP-12 transcript was shown to be
upregulated at the lesion epicenter 5 days after injury,19
MMP-12 expression was not detected in any of the spinal
cord samples in the present study. As MMP-12 KO mice were
Fig. 7. Quantification of the changes in MMP protein levels at different time points after PSNL. Equal amounts (30 mg) of total protein extract were prepared at
different time points, and expression profiles of MMP-2, -9, -17, and -24 in animals following PSNL were detected. b-actin was used as an endogenous control for
normalization of the amount of total protein in each sample (*p < 0.05 relative to control). MMPs ¼ matrix metalloproteinases; PSNL ¼ partial sciatic nerve
ligation.
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human MMP-12 augmented inflammatory arthritis in trans-
genic rabbits,8,37 a role for MMP-12 during inflammation is
well established. However, the discrepancy between data
from previous reports and those from the present study may
be related to the source of MMP-12. MMP-12, mainly pro-
duced by macrophages, is not detectable in normal adult
tissues but may be induced rapidly in tissues undergoing
remodeling.38,39 In the PSNL model, the activation of in-
flammatory cells is limited mainly to the peripheral nerve
lesion, providing a plausible explanation for negative MMP-
12 expression results in the spinal cord in the present study.
MMP-12 has been implicated as a critical element for CNS
development, as delayed myelin formation has been observed
in MMP-12 null mice.35 Therefore, further studies are needed
to elucidate the role(s) of MMP-12 during neuropathic pain
development.
MMP-17 was also detected immediately after PSNL, and
its high expression was maintained throughout the experiment.
MMP-17 is also known as a membrane type 4 MMP and was
first identified in human breast carcinoma.40 MMP-17 is
expressed in the brain, spinal cord dorsal horn, colon, ovary,
testes, and immune cells.24 Despite its noticeable presence in
the brain and spinal cord, very little is known of its physio-
logical functions in the nervous system. However, it has been
suggested that MMP-17 promotes TNF-a convertase activity,
and that MMP-17 upregulation has been demonstrated in
infection and inflammation models.41e43 Therefore, it is
plausible that MMP-17 may participate in the development of
neuropathic pain, as the presence of MMP-17 would increaseTNF-a production and thus contribute to the inflammatory
responses in mice subjected to PSNL.
Similar to that for MMP-17, data from the present study
showed that MMP-24 expression was observed immediately
after PSNL and that its high expression level was maintained
throughout the experiment. MMP-24 is a membrane type 5
MMP, recognized as a neuron-specific MMP because its
expression is specifically detected in neurons of the CNS and
peripheral nervous system, and has been implicated in neu-
ronal axonal growth and plasticity.11,44e46 Interestingly, recent
evidence demonstrated that mice with genetically ablated
MMP-24 demonstrated a lowered severity of neuropathic
allodynia after PSNL or spinal cord transection.11 This may be
attributable to MMP-24-mediated degradation of chondroitin
sulfate proteoglycans, which are abundant in neuronal tissues
and inhibit neurite outgrowth.23,47,48 Furthermore, histological
tracing studies with cholera toxin B indicated that myelinated
Ad afferent fibers sprouted and invaded from laminae III and
VI to II in wild-type mice, whereas no sprouting and invasion
of nerve fibers were observed in MMP-24-deficient mice.11
These data suggest that MMP-24 may be involved in neuro-
nal plasticity and modification during neuropathic pain
development.
The hypothesis that neuronal plasticity remodeling during
chronic neuropathic pain requires the concerted expression of
specific MMPs is plausible provided that both temporal and
spatial differential expression of MMPs are necessary and
beneficial to the plasticity or recovery of the CNS.45 The re-
sults of the present study document the expression profiles of
neuropathic pain-related MMPs, which may contribute to
Fig. 8. Representative double-immunofluorescence images showing differences in the cellular expression profile between different MMPs after PSNL. MMP-2 was
expressed in GFAP-positive astrocytes (I) but not in neuron and microglia cells (A and E). MMP-9, MMP-17, and MMP-24 were expressed in neuron (B, C, and D)
and microglial (F, G, and H) cells but were not expressed in astrocytes (J, K, and L). MMPs ¼ matrix metalloproteinases; PSNL ¼ partial sciatic nerve ligation.
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during neuropathic pain development.Acknowledgments
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